- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Outlook Therapeutics, Inc. is seeking approval from the FDA for its LYTENAVA™ product.
10 reports, 4 independent
Updated Aug 14
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 10
- Developments
- 6
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Outlook Therapeutics, Inc. is seeking approval from the FDA for its LYTENAVA™ product.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA grants approval for LYTENAVA for wet AMD, paving the way for commercial launch.1 source
The drug LYTENAVA was launched by Outlook Therapeutics in Austria.1 source
FDA approved LYTENAVA for wet AMD.1 source
Outlook Therapeutics applied to the FDA for approval of LYTENAVA™.1 source
Outlook Therapeutics seeks FDA feedback on its product via a Type A Meeting request.1 source
Resubmitted BLA for LYTENAVA™ approval and commenced commercial launch.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Teva's acquired product is currently undergoing review by the FDA.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Experimental therapies require approval from the FDA.
Coverage
Newest first; wire copies grouped- manilatimes.net
- manilatimes.net
- yahoo.com
- manilatimes.net
- GlobeNewswireOutlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company
- GlobeNewswireOutlook Therapeutics Requests Type A Meeting with FDA ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the
- BenzingaFDA Rejects Outlook Therapeutics Eye Drug For Second Time Outlook Therapeutics, Inc. (NASDAQ:OTLK) stock plunged on Thursday after the U.S. Food and Drug Administration (FDA) update. Outlook Therapeu
- GlobeNewswireOutlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq:
- GlobeNewswireOutlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE)